Desvenlafaxine Tablet, Extended Release
Product Images NDC 63304-192

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Desvenlafaxine (NDC 63304-192). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sun Pharmaceutical Industries, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

30's Bottle Pack (Desvenlafaxine 100mg)

This is a packaging label for a medication containing 100mg of desvenlafaxine in each tablet. The recommended dosage and storage instructions are also provided. The medication is meant to be dispensed with a medication guide provided to each patient. The medication is distributed by Sun Pharmaceutical Industries in New Jersey, USA.*

FDA Label Image

30's Bottle Pack (Desvenlafaxine 50mg)

This is the packaging of desvenlafaxine extended-release tablets manufactured and formulated by Alembic Pharmaceuticals Limited. The package includes 30 sealed tablets with accompanying medication guide intended to be dispensed as a 2-unit dosage. The usual dosage is not mentioned but can be found in the package insert. The tablets should be stored between 20°C to 25°C (68°F to 77°F) with excursions permitted up to 15°C to 30°C (59°F to 85°F). It is distributed in the USA by Sun Pharmaceutical Industries and has a National Drug Code (NDC) of 63304-191-30.*

FDA Label Image

Desvenlafaxine Figur4

This is a graph showing the estimated proportion of patients with relapse over time, with the x-axis indicating time to relapse in days from randomization and the y-axis indicating the percentage of patients experiencing relapse. The graph compares the relapse rates between Desvenlafaxine Extended-Release Tablets 50mg and a placebo treatment. The text does not provide any further information on the study or its results.*

FDA Label Image

Desvenlafaxine Figur5

This is a graph depicting the estimated proportion of patients with relapse over time, with time to relapse in days from randomization on the horizontal axis and the percentage of patients with relapse on the vertical axis. The graph compares Desvenlafaxine Extended-Release Tablets to a placebo. The data points on the graph represent percentages of patients with relapse at specific time intervals. The vertical axis has labels of 3, 5, 8, and B, which presumably correspond to the percentages reflected in the data.*

FDA Label Image

Desvenlafaxine Figure1

FDA Label Image

Desvenlafaxine Figure2

This appears to be a table showing the changes in CYP3A4 inhibitors with ketoconazole. The table shows the Cmax and AUC of Ketoconazole with geometric means ratios and confidence intervals. The change is relative to the reference.*

FDA Label Image

Desvenlafaxine Figure3

FDA Label Image

Structure (Desvenlafaxine Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.